All Stories

  1. High-throughput assay to simultaneously evaluate activation of CYP3A and the direct and time-dependent inhibition of CYP3A, CYP2C9, and CYP2D6 using liquid chromatography-tandem mass spectrometry

    Article • Xenobiotica, February 2024, Taylor & Francis

    Dr Yoshikazu Abe

  2. Non-clinical studies indicating lack of interactions between iron/calcium ions and linzagolix, an orally available GnRH antagonist

    Article • Xenobiotica, May 2022, Taylor & Francis

    Dr Yoshikazu Abe

  3. Ameliorating effect of rovatirelin on the ataxia in rolling mouse Nagoya

    Article • European Journal of Pharmacology, September 2020, Elsevier

    Dr Yoshikazu Abe

  4. Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P‐Glycoprotein Inhibitor (Itraconazole)

    Article • The Journal of Clinical Pharmacology, May 2020, Wiley

    Dr Yoshikazu Abe

  5. Quantitative Evaluation of Reactivity and Toxicity of Acyl Glucuronides by [35S]Cysteine Trapping

    Article • Chemical Research in Toxicology, September 2019, American Chemical Society (ACS)

    Dr Yoshikazu Abe

  6. Human mass balance, pharmacokinetics and metabolism of rovatirelin and identification of its metabolic enzymes in vitro

    Article • Xenobiotica, February 2019, Taylor & Francis

    Dr Yoshikazu Abe

  7. Pharmacokinetics of mizagliflozin, a novel selective SGLT1 inhibitor, in rats

    Article • Xenobiotica, March 2018, Taylor & Francis

    Dr Yoshikazu Abe

  8. Non-clinical pharmacokinetic profiles of rovatirelin

    Article • Xenobiotica, January 2018, Taylor & Francis

    Dr Yoshikazu Abe

  9. Development and validation of an LC–MS/MS method for simultaneously determining doxapram and keto-doxapram in human serum

    Article • Bioanalysis, March 2017, Future Science

    Dr Yoshikazu Abe

  10. Drug-drug interaction with the OAT inhibitor

    Article • Clinical Pharmacology in Drug Development, September 2015, Wiley

    Dr Yoshikazu Abe